Greenwich LifeSciences, Inc. - Common stock (GLSI)

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Greenwich LifeSciences, Inc. (NASDAQGLSI) concerning the Company and its directors’ and officers’ possible violations of state laws.

Greenwich LifeSciences just reported results for the second quarter of 2024.

GLSI stock results show that Greenwich LifeSciences beat analyst estimates for earnings per share the first quarter of 2024.

Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades.

Greenwich LifeSciences, Inc. (NASDAQGLSI) is one of today’s top gainers. The company’s shares have moved 33.96% on the day to $11.13.

GLSI stock results show that Greenwich LifeSciences missed analyst estimates for earnings per share the fourth quarter of 2023.

Greenwich Lifesciences shares are trading higher by 30.6% Wednesday afternoon. The company provided an update on the Phase III clinical trial, Flamingo-01.

Although US stocks closed higher on Tuesday, there were a few notable insider trades.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following year end update.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company’s directors, officers, and existing pre-IPO investors to December 31, 2023 which is approximately 39 months from date of the Company’s IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modified by the Board of Directors.

Potential short squeeze plays gained steam in 2021 and has continued through 2022 with new traders looking for the next huge move.

Gainers Kalera Public Limited Company (NASDAQKAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share.

Potential short squeeze plays gained steam in 2021 and has continued through 2022 with new traders looking for the next huge move. Here’s a look at the top five short squeeze candidates based on the Fintel short squeeze leaderboard.

Short-squeeze stocks continue to be a big deal for speculative traders and we're helping them out with a list to keep in mind this week!

Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. Here’s a look at the top five short squeeze candidates based on the Fintel short squeeze leaderboard.

Short squeeze stocks are still popular with speculative traders and that has us going over the top ones to keep an eye on this week!

Investors are still interested in short squeeze stocks lately and we've got them covered with the ones to watch this week!

Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. Here’s a look at the top five short squeeze candidates for the week of Oct. 3 based on the Fintel short squeeze leaderboard.

Traders continue to show interest in short squeeze stocks this week as they seek out likely targets that will run higher.

Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. Here’s a look at the top five short squeeze candidates for the week of Sept. 19, according to Fintel Data: